
Sign up to save your podcasts
Or


AstraZeneca’s vaccine gets UK approval, but the FDA has yet to decide. Bill Barker analyzes that story, reacts to 2021 precitions about the price of oil and a return to domestic travel, and shares why future investors might not realize how crazy 2020 was for the stock market.
By The Motley Fool4.7
16041,604 ratings
AstraZeneca’s vaccine gets UK approval, but the FDA has yet to decide. Bill Barker analyzes that story, reacts to 2021 precitions about the price of oil and a return to domestic travel, and shares why future investors might not realize how crazy 2020 was for the stock market.

3,217 Listeners

1,482 Listeners

808 Listeners

944 Listeners

521 Listeners

1,170 Listeners

2,201 Listeners

825 Listeners

1,422 Listeners

1,038 Listeners

9,715 Listeners

195 Listeners

833 Listeners

84 Listeners

584 Listeners

1,049 Listeners

56 Listeners